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RESUMEN
La 5-metil-2,4-dihidro-3H-pirazol-3-ona (1) reacciona con 
benzaldehídos substituidos (2a-d) en presencia de acetato 
sódico anhidro para dar las correspondientes 4-ariliden-
5-metil-2,4-dihidro-3H-pirazol-3-onas (3a-d). La conden-
sación subsiguiente de 3a-d con 2-bromoetoxi-1H-isoin-
dol-1,3-(2H)-diona (II) en presencia de piridina como base 
proporciona las 2-[2-(4-ariliden-3-metil-5-oxo-4,5-dihi-
dropirazol-1-il)etoxi]-isoindol-1,3-dionas (4a-d), que por 
ciclación con nicotinhidrazida (I) rinden los compuestos 
del título, 6-N- etoxiftalimido-3-(fenil substituido)-4-me-
til-3a,6-dihidropirazolo[3,4-c]pirazol-2(3H)-il(piridin-3-il)
metanona (5a-d). Todos los compuestos sintetizados se 
caracterizan mediante análisis elemental y datos espec-
troscópicos, y se ensayan en busca de diversas activida-
des antimicrobianas y antivirales.
Palabras clave: Pirazolo[3,4-c]pirazoles, Nicotinhidrazida, 
Bromuro de ftalimidoxietilo, Actividad antivírica.
SUMMARY
5-Methyl-2,4-dihydro-3H-pyrazol-3-one (1) reacted with 
substituted benzaldehydes (2a-d) in the presence of an-
hydrous sodium acetate to gave corresponding 4-aryli-
dene-5-methyl-2,4-dihyro-3H-pyrazol-3-ones (3a-d). 
Further condensation of (3a-d) with 2-bromoethoxy-1H-
isoindole-1,3-(2H)-dione (II) in the presence of pyridine as 
a base furnished 2-[2-(4-arylidene-3-methyl-5-oxo-4,5-
dihydro-pyrazol-1-yl)ethoxy]-isoindole-1,3-diones (4a-d), 
which on cyclisation with nicotinohydrazide (I) afforded 
titled compounds 6-N- ethoxyphthalimido-3-(substituted 
phenyl)-4-methyl-3a,6-dihydro pyrazolo[3,4-c]pyrazol-
2(3H)-yl(pyridin-3-yl)methanone (5a-d). All the synthesized 
compounds have been characterized by elemental analy-
sis and spectral data and were screened for various anti-
microbial and antiviral activities.
Keywords: Pyrazolo[3,4-c]pyrazoles, Nicotinohydrazide, 
Phthalimidoxyethyl bromide, Antiviral activities. 
RESUM
La 5-metil-2,4-dihidro-3H-pirazol-3-ona (1) reacciona amb 
benzaldehids substituïts (2a-d) en presència d’acetat sò-
dic anhidre per donar les corresponents 4-ariliden-5-me-
til-2,4-dihidro-3H-pirazol-3-ones (3a-d). La condensació 
subsegüent de 3a-d amb 2-bromoetoxi-1H-isoindole-1,3-
(2H)-diona (II) en presència de piridina com a base pro-
porciona les 2-[2-(4-ariliden-3-metil-5-oxo-4,5-dihidro-
pirazol-1-il)etoxi]-isoindole-1,3-diones (4a-d), que per 
ciclització amb nicotinhidrazida (I) rendeixen els compos-
tos del títol, 6-N- etoxiftalimido-3-(fenil substituït)-4-me-
til-3a,6-dihidropirazolo[3,4-c]pirazol-2(3H)-il(piridin-3-il)
metanona (5a-d). Tots els compostos sintetitzats es carac-
teritzen mitjançant anàlisi elemental i dades espectroscò-
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INTRODUCTION
Pyrazoles are interesting group of compounds possess-
ing widespread pharmacological properties, such as an-
tidiabetic1, analgesic, antipyretic, antidepressant and an-
tirheumatic2 and are also well known for their pronounced 
anti-inflammatory activity3. Recently, pyrazoles have been 
reported as a DP-IV inhibitor and antitumor agents4-6. It is 
interesting to note that fused bis-pyrazoles are reported 
as well known pharmacophores7,8. It has been consid-
ered worthwhile to incorporate a suitable functionality 
into these derivatives to potentiate their pharmacological 
activity9,10 Several derivatives of alkoxyphthalimide have 
been synthesized11,12 by our research group and reported 
to demonstrate a wide range of pharmacological activi-
ties viz. anticancer, antimalarial and antimicrobial etc13,14. 
In view of the above mentioned facts and in connection 
with our on going work of synthesizing alkoxyphthalimide 
derivatives15,16 of heterocyclic systems led us to undertake 
the synthesis of some new combinational molecules, in-
corporating above moieties in them with the hope to result 
in increased biological activities.
EXPERIMENTAL
Melting points were determined in open capillary tubes and 
are uncorrected. The time required for completion of the 
reaction was monitored by TLC using Silica gel-G plates 
and spots were exposed in iodine chamber. IR spectra 
were recorded on a Perkin Elmer 1800 (FTIR) spectrom-
eter 1H NMR spectra (DMSO) were taken on a DRX-300 
spectrometer (300 MHz) using TMS as internal standard 
and chemical shifts are expressed in d ppm. Mass spec-
tra were taken on a jeol SX-102/DA-6000 spectrometer. 
Phthalimidoxyethylbromide (II) was prepared17 by reported 
methods.
Synthesis of nicotinic hydrazide (I): 
A mixture of ethyl nicotinate (0.05mole) in ethanol (25ml) 
and hydrazine hydrate (0.05mole) is refluxed for 10-12 hrs. 
After cooling the solid product obtained is filtered, washed, 
dried and recrystallized from ethanol. White needle shaped 
crystals of (I) are obtained.
Synthesis of 4-benzylidene-5-methyl-2,4-dihyro-3H-
pyrazol-3-one (3a): 
A mixture of 5-methyl-2, 4-dihydro-3H-pyrazol-3-one (1) 
(0.01 mole), benzaldehyde (2a) (0.01 mole) and anhydrous 
sodium acetate (0.01 mole) were suspended in acetic acid 
(25 ml) and refluxed for 14 hrs. The reaction mixture was 
filtered and the filtrate was poured on crushed ice. The 
solid obtained was crystallized from ethanol. Compounds 
(3b-d) were also synthesized by the similar method using 
appropriate reactants with required changes in reflux time.
Synthesis of N-ethoxyphthalimido-4-benzylidene-
5-methyl-2,4-dihyro-3H-pyrazol-3-one (4a): 
A mixture of (3a-d, 0.01mol) and 2-bromoethoxy-1H-isoin-
dole-1,3-(2H)-dione (0.01mol) were dissolved in ethanol. 
Pyridine (0.01mol) was added to this reaction mixture as a 
base. The reaction mixture was refluxed for 16 hrs. 
The filtrate was poured into crushed ice and the solid ob-
tained was filtered, dried and recrystallized from ethanol. 
Compounds (4b-d) were also synthesized by the similar 




A mixture of compound (4a) (0.01 mole), and nicotinohy-
drazide ( I, 0.01 mole) were refluxed in glacial acetic acid 
(25 ml) for 10 hrs. The reaction mass filtered, excess of 
the solvent from the filtrate was removed under reduced 
pressure. On cooling, the solid separated was crystallized 
from ethanol. Compounds (5b-d) were also synthesized by 
the similar method using appropriate reactants and minor 
modification in reaction conditions.
RESULTS AND DISCUSSION
4-arylidene-5-methyl-2,4-dihyro-3H-pyrazol-3-ones 
(3a-d) were synthesized by the reaction of 5-methyl-2, 
4-dihydro-3H-pyrazol-3-one (1) with substituted benzal-
dehydes  (2a-d) in the presence of anhydrous sodium ac-
etate. Formation of (3a) was characterized by one singlet 
in 1H NMR at d 6.13 ppm of C=CH-Ar. Compounds (3a-d) 
were further condensed with 2-bromoethoxy-1H-isoin-
dole-1,3-(2H)-dione II in the presence of pyridine to yield 
2-[2-(4-arylidene-3-methyl-5-oxo-4,5-dihydro-pyrazol-




3424, 3207 (N-H str.), 1656 (C=O str.), 1597 (C=N str.).




3421(N-H), 3068(Ar-H), 2928(C-H,CH3), 1688(C=O), 1574 (C=N) 8.28 (s, 1H, 




3447(N-H), 3076 (Ar-H), 2974 (C-H, CH3), 1695(C=O), 1563 (C=N), 767(C-Cl).




3418 (N-H), 3083 (Ar-H), 2967 (C-H, CH3), 1677 (C=O), 1586 (C=N)8.32 (s, 1H, Ar-CH=).




3429 (N-H),3067 (Ar-H), 2953 (C-H, CH3),1687 (C=O),1595 (C=N)




3048 (Ar-H), 2938 (C-H, CH3), 2857 (C-H, CH2), 1751, 1683 (C=O), 1597 (C=N), 1397 (N-O), 1105 (C-O).




3056 (Ar-H), 2947 (C-H, CH3), 2861 (C-H, CH2), 1744, 1675 (C=O), 
1588 (C=N), 1350 (N-O), 1165 (C-O), 728 (C-Cl).




3096 (Ar-H), 2964 (C-H, CH3), 2828 (C-H, CH2),1757, 1690 (C=O), 1601 (C=N), 1384 (N-O), 1139 (C-O)
7.79-7.23 (m, 8H, Ar-H),6.15 (s, 1H, C=CH-Ar), 4.39 (t, 2H, OCH2), 3.63 
(s, 3H, OCH3), 3.24 (t, 2H, NCH2), 1.89 (s, 3H, CH3).
Table I :  Spectral data of synthesized compounds 1-5 a-d
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1-yl)ethoxy]-isoindole-1,3-diones (4a-d). Disappearance 
of NH stretching band at 3421 cm-1 in the IR spectra (4a) 
confirmed that the replacement of hydrogen of pyrazole 
by ethoxyphthalimide, which was present in its precur-
sor. Additional proof for the proposed structure of (4a) 
was provided by close observation of 1H NMR spectra, 
which showed disappearance of NH signal at d 8.28 and 
appearance of two triplets for NCH2 and OCH2 protons at 
d 3.18 and 4.34 respectively. Compounds (4a-d) on fur-
ther cyclization with nicotinohydrazide (I) in glacial acetic 
acid furnished final compounds (5a-d). Cyclization were 
confirmed by the disappearance of singlet for C=CH-Ar in 
1H NMR spectra. Structural assignments of all the synthe-
sized compounds are based on IR, 1H NMR, mass spectral 
data and elemental analysis.
Antiviral testing
Four final compounds were screened for antiviral activity 
against influenza A (H1N1 and H3N2 subtypes) and influ-
enza B viruses and cytotoxicity in MDCK (Madin Darby 
Canine Kidney) cells. Results have been expressed in the 
form of EC50 values (Effective concentration or concentra-
tion producing 50% inhibition of virus-induced cytopathic 
effects as determined by visual scoring of the CPE or by 
measuring the cell viability with the colorimetric formazan 
based MTS assay).
The reference compounds oseltavimir carboxylate and 
ribavirin were active against influenza virus; their EC50 val-
ues are clearly lower than their MCC value (concentrations 
causing minimal toxicity). For amantadin and rimantidin, 
the best activity was seen with the H3N2 strain. These 
compounds are known to be inactive against influenza B. 
Also the H1N1 strain that is used in tests is known to be 
less sensitive to amantadin and rimantadin. Among the 
range of thirteen compounds tested, none was able to in-
hibit the cytopathic effects of influenza A or B at subtoxic 
concentration or at the highest concentration tested (100 
mg/mL). 
Cytotoxicity and antiviral activity of synthesized com-
pounds in HEL, HeLa and Vero cell cultures
Antiviral assay in HEL, HeLa and Vero cells with the four 
compounds (5a-d) have been observed on Herpes sim-
plex virus-1 & 2, Vaccinia virus, Vesicular stomatitis virus, 
Coxsackie virus B4, Respiratory syncytical virus, Para-in-
fluenza-3 virus, Reovirus-1 and Puntatoro virus. No specif-
ic antiviral effects (i.e. minimal antivirally effective concen-
tration) were noted for any of the compounds evaluated 




3062 (Ar-H), 2942 (C-H, CH3), 2857 (C-H, CH2),1745, 1687 (C=O), 1589 (C=N), 1365 (N-O), 1156 (C-O)




3081 (Ar-H), 2923 (C-H, CH3), 2854 (C-H, CH2), 1767, 1693 (C=O), 
1589 (C=N), 1376 (N-O str.) 1098 (C-O str.).
 43-6.95 (m, 13H, Ar-H), 4.65 (t, 2H, OCH2), 4.45 (d, 1H, CH-Ar),  3.98 




3068 (Ar-H), 2932 (C-H, CH3), 2830 (C-H, CH2), 1746, 1691 (C=O), 
1618 (C=N), 1375 (N-O str.) 1087 (C-O str.),702 (C-Cl).
8.21-7.26 (m, 12H, Ar-H), 4.41 (t, 2H, OCH2),  4.24 (d, 1H, CH-Ar),  3.84 




3072 (Ar-H), 2942 (C-H, CH3), 2848 (C-H, CH2), 1756, 1701 (C=O), 
1610 (C=N), 1360 (N-O str.) 1080 (C-O str.).
8.30-7.17 (m, 12H, Ar-H), 4.65 (t, 2H, OCH2), ),4.38 (d, 1H, CH-Ar), 3.95 (t, 2H, 




3080 (Ar-H), 2931 (C-H, CH3), 2868 (C-H, CH2), 1749, 1685 (C=O), 
1595 (C=N), 1355 (N-O str.) 1065 (C-O str.).
8.41-7.08 (m, 12H, Ar-H), 4.61 (t, 2H, OCH2),  4.50 (d, 1H, CH-Ar), 3.97 
(t, 2H, CH-C), 3.36  (t, 2H, NCH2), 2.07 (s, 3H, CH3).
Compds Mol.Formula Mol.wt. M.P. (°C) Yield (%) Calc./found N
1 C6H7N3O 137 162 70 30.64 / 30.52
3ª C11H10N2O 186 170 75 15.04 / 14.95
3b C11H9ClN2O 220 155 62 12.70 / 12.63
3c C12H12N2O2 216 166 63 12.96 / 12.90
3d C11H9N3O3 231 165 69 18.17 / 18.10
4a C21H17N3O4 375 172 63 11.19 / 11.12
4b C21H16ClN3O4 409 143 62 10.25 / 10.19
4c C22H19N3O5 405 132 59 10.37 / 10.27
4d C21H16N4O6 420 138 65 13.33 / 13.29
5a C27H22N6O4 494 276 51 17.0 / 17.03
5b C27H21ClN6O4 528 >300 53 15.9/ 15.85
5c C28H24N6O5 524 281 55 16.0 / 15.92
5d C27H21N7O6 539 >300 51 18.2 / 18.24
 Table II: Physical and analytical data of synthesized compounds
Comp.
Antibacterial activity Antifungal activity
B. subtilis E. coli S. typi P. aeruginosa  C. albicans A. fumigates
5a 17(0.85) 170(.80) 21(1.10) 17(0.89) 19(0.90) 19(1.0)
5b 19(0.95) 23(1.09) 18(0.94) 17(.80) 18(0.85) 19(1.0)
5c 17(0.85) 16(0.76) 20(1.05) 16(0.76) 16(0.76) 20(1.05)
5d 15(0.75) 18(0.85) 17(0.89) 20(0.95) 19(0.90) 14(0.73)
Standard 20 21 19 21 21 19
Table III : Antibacterial and antifungal activity (500 ppm) / Zone of inhibition (mm)
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Antimicrobial activity
The title compounds (5a–d) were screened for their anti-
bacterial and antifungal activities using cup and well meth-
od 18. Antibacterial activity of compounds (500μg/ml) have 
been evaluated against four bacterial strain viz. E. coli, 
P. aeruginosa, S. typi and B.subtilis. Almost all the com-
pounds showed low to moderate activity against E coli, P. 
aeruginosa and S.typi. Screening of the title compounds 
(500μg/ml) for antifungal activity was carried out against 
two fungal strain viz. A. fumigates and C. albicans using 
flucanazole as a standard drug. Compounds 5a-d   were 
good to moderate active against A. fumigatus. and C. al-
bicans (table 3). 
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